Cancer of unknown primary site

New England Journal of Medicine

Volumn 371, Issue 8, 2014, Pages 757-765

  Varadhachary, Gauri R ^a   Raber, Martin N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; VEMURAFENIB;

BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER OF UNKNOWN PRIMARY SITE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; GENOMICS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHADENOPATHY; MASTECTOMY; METASTASIS; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

HUMANS; INDIVIDUALIZED MEDICINE; MULTIMODAL IMAGING; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84907302559     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1303917     Document Type: Review

References (49)

1. Briasoulis E, Tolis C, Bergh J, Pavlidis N. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2005;16:Suppl 1:i75-i76. (Pubitemid 40872998)
2. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2008:2363-87.
3. Rubin BP, Skarin AT, Pisick E, Rizk M, Salgia R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev 2001;10:77-82. (Pubitemid 32200205)
4. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008;132:384-96. (Pubitemid 351328813)
5. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-93. (Pubitemid 30641873)
6. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-72. (Pubitemid 40685594)
7. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995;15:2563-7. (Pubitemid 26098613)
8. Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications: a Hellenic Co-operative Oncology Group study. Anticancer Res 1998;18:1907-14. (Pubitemid 28344848)
9. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000;18:632-5. (Pubitemid 30078544)
10. Hillen HF, Hak LE, Joosten-Achjanie SR, Arends JW. Microvessel density in unknown primary tumors. Int J Cancer 1997;74:81-5. (Pubitemid 27157860)
11. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005;5:25.
12. Hale KS, Wang H, Karanth S, et al. Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. J Clin Oncol 2012;30:Suppl. abstract.
13. National Comprehensive Cancer Network. Occult primary (cancer of unknown primary), version 1. 2013 (http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#site).
14. Taylor MB, Bromham NR, Arnold SE. Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol 2012;85:661-71.
15. Varadhachary GR. Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw 2011;9:1406-12.
16. Schelfout K, Kersschot E, Van Goethem M, et al. Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy. Eur Radiol 2003;13:2128-32. (Pubitemid 37080748)
17. Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7:411-5. (Pubitemid 30439299)
18. Lu H, Xu YL, Zhang SP, et al. Breast magnetic resonance imaging in patients with occult breast carcinoma: evaluation on feasibility and correlation with histopathological findings. Chin Med J (Engl) 2011;124:1790-5.
19. Joshi U, van der Hoeven JJ, Comans EF, Herder GJ, Teule GJ, Hoekstra OS. In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET. Br J Radiol 2004;77:1000-6. (Pubitemid 40057796)
20. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004;101:2641-9. (Pubitemid 39532297)
21. Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011; 33:935-40.
22. Randall DA, Johnstone PA, Foss RD, Martin PJ. Tonsillectomy in diagnosis of the unknown primary tumor of the head and neck. Otolaryngol Head Neck Surg 2000;122:52-5. (Pubitemid 30051689)
23. Moller AK, Loft A, Berthelsen AK, et al. 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist 2011;16:445-51.
24. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986;104:547-53. (Pubitemid 16137818)
25. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993;329:257-63. (Pubitemid 23203818)
26. Oien KA, Dennis JL. Diagnostic workup of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 2012;23:Suppl 10:x271-x277.
27. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011;17:4063-70.
28. Varadhachary GR, Karanth S, Qiao W, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 2013 June 28 (Epub ahead of print).
29. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007;43:2026-36. (Pubitemid 47380362)
30. Bloom G, Yang IV, Boulware D, et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004;164:9-16. (Pubitemid 38364584)
31. Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-40. [Erratum, Cancer Res 2005;65:8057.] (Pubitemid 40775639)
32. Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012;18:3952-60.
33. Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a microarraybased gene expression test for tumor identification in formalin-fixed, paraffinembedded specimens. J Mol Diagn 2011; 13:48-56.
34. Meiri E, Mueller WC, Rosenwald S, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist 2012;17:801-12.
35. Ferracin M, Pedriali M, Veronese A, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011;225:43-53.
36. Horlings HM, van Laar RK, Kerst JM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008;26:4435-41.
37. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010;15:500-6.
38. Varadhachary G. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clin Cancer Res 2013;19:4027-33.
39. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. J Clin Oncol 2013;31: 217-23.
40. Handorf CR, Kulkarni A, Grenert JP, et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 2013;37:1067-75.
41. Weiss L, Chu P, Schroeder BE, et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 2013;15:263-9.
42. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003;21:3479-82. (Pubitemid 46594080)
43. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-7.
44. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-5. (Pubitemid 30148737)
45. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20:4679-83. (Pubitemid 36025285)
46. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008;9:596-9. (Pubitemid 351722584)
47. Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013;105: 782-90.
48. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
49. Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19:657-67.